Nuevolution A/S Company Profile

08:06 EDT 22nd October 2017 | BioPortfolio

Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics® enables rapid oligonucleotide e.g. DNA encoded synthesis of up to billions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented speed and scale.

Nuevolution partners its technology with pharmaceutical and biotechnology companies. Nuevolution has entered into agreements with Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis Pharma and Boehringer Ingelheim, where Lexicon Pharmaceuticals and GlaxoSmithKline have entered into licensing agreements with Nuevolution. In a 4 million budgeted project supported by the Danish Advanced Technology Fund, Nuevolution has initiated hit-to-lead optimization efforts. Nuevolution has also entered a scientific collaboration by and between Duke University, Howard Hughes Medical Institute, Lexicon Pharmaceuticals and Nuevolution. Most recently, Nuevolution announced a joint venture with Cancer Research Technology (CRT), the commercial arm of Cancer Research UK.

Nuevolution has demonstrated the power of Chemetics® by identification of highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes. Nuevolutions internal programs are focused on therapeutically important targets within inflammation and oncology.

Nuevolution is a privately owned company by key Scandinavian investors, including SEB Venture Capital, Sunstone Capital, Industrifonden, SLS Invest, Novo Ventures and Innoventus Life Sciences.


Rønnegade 8


Phone: 45 70 20 09 87
Fax: 45 70 20 09 86

News Articles [3 Associated News Articles listed on BioPortfolio]

Nuevolution (NUE) - Defining year as partnerships progress on track

Edison Investment Research - Pharmaceutical & healthcare - Nuevolution: FY17 has been a defining year for Nuevolution as it looks to further validate its unique Chemetics drug discovery platform. High...

Nuevolution Announces Its Results For The Fourth Quarter And Full Year 2016/17

  Life Sciences Jobs   ...

Nuevolution AB (publ) Announces its Results for the Fourth Quarter and Full Year 2016/17

STOCKHOLM, Sept. 06, 2017 /PRNewswire/ -- 8.30 AM CEST / 6-Sep-2017 / Nuevolution (SEMM: NUE) Nuevolution AB (publ) announces its report for the fourth quarter and full year 2016/17. The repor...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]

Nuevolution A/S

Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven...

More Information about "Nuevolution A/S" on BioPortfolio

We have published hundreds of Nuevolution A/S news stories on BioPortfolio along with dozens of Nuevolution A/S Clinical Trials and PubMed Articles about Nuevolution A/S for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nuevolution A/S Companies in our database. You can also find out about relevant Nuevolution A/S Drugs and Medications on this site too.

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Corporate Database Quicklinks

Searches Linking to this Company Record